LineaRx specializes in advanced DNA manufacturing technologies, primarily through its innovative LinearDNA™ platform. This platform utilizes a cell-free enzymatic approach to produce therapeutic DNA with enhanced speed, purity, and scalability compared to traditional plasmid DNA (pDNA) methods, which have remained largely unchanged for decades. The LinearDNA™ platform is designed to support a variety of nucleic acid-based therapies, including mRNA, cellular and gene therapies, and DNA vaccines. By leveraging their expertise in polymerase chain reaction (PCR), LineaRx aims to accelerate the development and commercialization of these therapies, ensuring that the next generation of medical treatments is supported by a robust supply of high-quality DNA.

Additionally, LineaRx has developed the Linea™ IVT technology, which combines their enzymatically-produced Linea DNA IVT templates with proprietary RNA polymerase. This combination streamlines the mRNA production process, significantly reducing or eliminating impurities while maintaining high yields. The advantages of the LinearDNA™ platform over traditional pDNA methods include a reduced risk of antibiotic resistance, lower endotoxin levels, and the ability to produce long, homogeneous poly-A tails essential for mRNA templates. Overall, LineaRx's technologies represent a significant advancement in the field of nucleic acid-based therapies, enabling faster and more efficient production of therapeutic DNA.

United States

Spindle Biotech Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) is commercializing a proprietary RNA polymerase for large-scale mRNA vaccine production. Recent advances in mRNA technology have shown the growing importance of synthetic RNA in biological systems due to its desirable transient property. Typical mRNA vaccine companies spend up to 60% of their cost of goods on raw materials such as enzymes and DNA templates. Spindle's platform provides a unique solution in producing high-quality RNA on-demand and in high yield, significantly reducing the cost of goods for mRNA production.

LineaRx

Company Details